(no subject)

Altig, Kathy (Kathy_Altig@phsor.org)
Fri, 17 Oct 1997 10:10:00 -0700

This message is in MIME format. Since your mail reader does not understand
this format, some or all of this message may not be legible.

------ =_NextPart_000_01BCDAE4.FA08A340
Content-Type: text/plain

We had a similar case, but after doing a literature source, elected
to
call it a Hairy Cell Variant. When I discussed this with the
clinician, he indicated that they treated cases like that as HCL.
(He
also said they tend to go with the peripheral morphology as a
bottom
line for diagnosis.) (???) Unfortunately, although the patient's
immediate response to therapy was good, it was not long lasting.
The
particular patient I was testing at that time reacted similarly. I

have re-flowed him each reoccurance, and the CD103 positivity and
CD25
negativity remain constant.

Kathy Altig
Providence Portland Med,Ctr.
Portland,OR

______________________________ Reply Separator
_________________________________
Subject: Author: ,stetler@box-s.nih.gov [SMTP:stetler@box-s.nih.gov] at
PHSOR
Date: 10/10/97 9:09 AM

I have a case that immunophenotypically looks like hairy cell
leukemia (monoclonal kappa, CD20 bright, CD22 bright, CD103+, CD11c+,
CD19+, FMC7 bright and negative for CD10, CD5,and CD23, however the CD25
is
negative). The peripheral blood smear looks like hairy cell. The
clinician
from another institute reports the bone marrow, which I haven't seen,
doesn't look like hairy cell and the patient is not low in platelets.
She
thinks it may be splenic marginal zone lymphoma. Has any one seen CD103+
on
a real splenic marginal zone lymphoma?

Maryalice

Maryalice Stetler-Stevenson
Director Flow Cytometry Unit
Laboratory of Pathology, NCI, NIH

------ =_NextPart_000_01BCDAE4.FA08A340
Content-Type: application/ms-tnef
Content-Transfer-Encoding: base64
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------ =_NextPart_000_01BCDAE4.FA08A340--